Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. It manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits; and offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. The company was incorporated in 2016 and is headquartered in La Jolla, California.
IPO Year: 2021
Exchange: NASDAQ
Website: singulargenomics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/17/2022 | $10.00 → $4.50 | Buy → Neutral | UBS |
8/10/2022 | $3.50 | Buy → Neutral | Goldman |
8/10/2022 | $3.00 | Buy → Underperform | BofA Securities |
1/7/2022 | $21.00 | Neutral → Buy | BofA Securities |
10/15/2021 | Outperform | Cowen |
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024. "The first quarter was productive and encouraging. We are focused on supporting our existing customers and getting the G4X spatial sequencer to market as quickly as possible," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "Looking ahead to the rest of the year, we plan to expand our spatial services offering a
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 14, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 173302
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023. "We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We continue to build momentum in early 2024 with the recent unveiling of the G4X, the first in situ spatial sequencer. The G4X brings sequencing int
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-877-545-0523 for domestic callers or 1-973-528-0016 for international callers and using confe
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023. "We shipped five G4 systems in the third quarter, our highest quarterly total yet, launched Max Read flow cell kits for single cell sequencing, and saw our largest number of quarterly consumable kit orders," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "In the near term, we will be building our installed base more
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 616134 approximately f
SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2023. "We made significant advancements across our operations, manufacturing and commercial infrastructure, and saw growth in our sales funnel. In addition, we shipped three G4 systems, commenced the broad commercial launch of F3 flow cells and consumable kits and are shipping Max Read kits for single cell sequencing to early access customers," said Drew Sp
SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at investor.singulargenomics.com, in the Presentations & Events section. About Singu
UBS downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $4.50 from $10.00 previously
Goldman downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $3.50
BofA Securities downgraded Singular Genomics Systems from Buy to Underperform and set a new price target of $3.00
BofA Securities upgraded Singular Genomics Systems from Neutral to Buy and set a new price target of $21.00
Cowen resumed coverage of Singular Genomics Systems with a rating of Outperform
BofA Securities initiated coverage of Singular Genomics Systems with a rating of Neutral and set a new price target of $26.00
Cowen initiated coverage of Singular Genomics Systems with a rating of Outperform
JP Morgan initiated coverage of Singular Genomics Systems with a rating of Overweight and set a new price target of $30.00
Goldman Sachs initiated coverage of Singular Genomics Systems with a rating of Buy and set a new price target of $35.00
SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13G/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13G/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13G/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13G/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13G/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13G/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SC 13G/A - Singular Genomics Systems, Inc. (0001850906) (Subject)
SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. "As an accomplished life science leader, Sam brings the deep knowledge and experi
LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. "We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, indust
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
10-Q - Singular Genomics Systems, Inc. (0001850906) (Filer)
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
10-Q - Singular Genomics Systems, Inc. (0001850906) (Filer)
8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
Goldman Sachs analyst Matthew Sykes maintains Singular Genomics Sys (NASDAQ:OMIC) with a Neutral and lowers the price target from $22.5 to $6.5.
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Enerpac Tool Group Corp. (NYSE:EPAC) to report quarterly earnings at 47 cents per share on revenue of $153.20 million after the closing bell. Enerpac Tool Group shares gained 1.9% to $39.22 in after-hours trading. Singular Genomics Systems, Inc. (NASDAQ:OMIC) reported a 1-for-30 reverse stock split. Singular Genomics shares fell 9.3% to $0.3180 in the after-hours trading session. Analysts are expecting Beyond Air, Inc. (NASDAQ:XAIR) to post a quarterly loss at $0.48 per share on revenue of $747.20 thousand. The company wil
Goldman Sachs analyst Matthew Sykes maintains Singular Genomics Sys (NASDAQ:OMIC) with a Neutral and lowers the price target from $0.85 to $0.75.
Singular Genomics Sys (NASDAQ:OMIC) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 3.03 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $442.00 thousand which beat the analyst consensus estimate of $390.00 thousand by 13.33 percent. This is a 48.78 percent decrease over sales of $863.00 thousand the same period last year.
Singular Genomics Sys (NASDAQ:OMIC) reported its Q4 earnings results on Monday, March 18, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Singular Genomics Sys beat estimated earnings by 6.0%, reporting an EPS of $-0.32 versus an estimate of $-0.34. Revenue was up $316 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.07 which was followed by a 7.000000000000001% increase in the share price the next day. Here's a look at Singular Genomics Sys's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.38 -0.37 -0.35 -0.43 EPS Actual -0.31 -0.35 -0.33 -0.29 Revenue Esti
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received an unsolicited non-binding proposal from Concentra Biosciences, LLC ("Concentra") to acquire all of the Company's outstanding shares of common stock for $12.00 per share in cash. As alternative consideration, Concentra stated that it would consider, assuming it receives sufficient interest from existing stockholders, inviting interested stockholders to elect to continue to participate in any future value realized from the Company
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, "Deerfield"), to acquire all of the Company's outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it received formal notice from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. As previously disclosed, on July 17, 2023, Singular Genomics received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq's listing requirements because the closing bid price
SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that on June 26, 2024, effective at 12:01 a.m. Eastern Time, it will effectuate a 1-for-30 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on June 26, 2024 under its current trading symbol "OMIC". The CUSIP number of the Company's common stock following the reverse stock split will be 82933R 308. The reverse stock split is intended to enable the Company to regain complia
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida. Singular Genomics' management is scheduled to participate in a fireside chat Wednesday, June 12, 2024, at 7:40 a.m. Pacific Time / 10:40 a.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com in the Presentations & Events section. About Singular G
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024. "The first quarter was productive and encouraging. We are focused on supporting our existing customers and getting the G4X spatial sequencer to market as quickly as possible," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "Looking ahead to the rest of the year, we plan to expand our spatial services offering a
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 14, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 173302
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023. "We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We continue to build momentum in early 2024 with the recent unveiling of the G4X, the first in situ spatial sequencer. The G4X brings sequencing int
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
3 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)
4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)